Format

Send to

Choose Destination
Eur Urol. 2016 May;69(5):855-62. doi: 10.1016/j.eururo.2015.08.034. Epub 2015 Sep 3.

A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.

Author information

1
Department of Urology, U.T. M.D. Anderson Cancer Center, Houston, TX, USA; Department of Cancer Biology, U.T. M.D. Anderson Cancer Center, Houston, TX, USA.
2
Department of Urology, U.T. M.D. Anderson Cancer Center, Houston, TX, USA.
3
Department of Statistics, U.T. M.D. Anderson Cancer Center, Houston, TX, USA.
4
Department of Genitourinary Medical Oncology, U.T. M.D. Anderson Cancer Center, Houston, TX, USA.
5
Essentia Health, Duluth, MN, USA.
6
Department of Pathology, U.T. M.D. Anderson Cancer Center, Houston, TX, USA.
7
Department of Genitourinary Medical Oncology, U.T. M.D. Anderson Cancer Center, Houston, TX, USA. Electronic address: asiefker@mdanderson.org.

Abstract

BACKGROUND:

Gene expression profiling (GEP) suggests there are three subtypes of muscle-invasive urothelial cancer (UC): basal, which has the worst prognosis; p53-like; and luminal. We hypothesized that GEP of transurethral resection (TUR) and cystectomy specimens would predict subtypes that could benefit from chemotherapy.

OBJECTIVE:

To explore clinical outcomes for patients treated with dose-dense (DD) methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) and bevacizumab (B) and the impact of UC subtype.

DESIGN, SETTING, AND PARTICIPANTS:

Sixty patients enrolled in a neoadjuvant trial of four cycles of DDMVAC + B between 2007 and 2010. TUR and cystectomy specimens for GEP were available from 38 and 23 patients, respectively, and from an additional confirmation cohort of 49 patients treated with perioperative MVAC.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS:

Relationships with outcomes were analyzed using multivariable Cox regression and log-rank tests.

RESULTS AND LIMITATIONS:

Chemotherapy was active, with pT0N0 and ≤pT1N0 downstaging rates of 38% and 53%, respectively, and 5-yr overall survival (OS) of 63%. Bevacizumab had no appreciable impact on outcomes. Basal tumors had improved survival compared to luminal and p53-like tumors (5-yr OS 91%, 73%, and 36%, log-rank p=0.015), with similar findings on multivariate analysis. Bone metastases within 2 yr were exclusively associated with the p53-like subtype (p53-like 100%, luminal 0%, basal 0%; p ≤ 0.001). Tumors enriched with the p53-like subtype at cystectomy suggested chemoresistance for this subtype. A separate cohort treated with perioperative MVAC confirmed the UC subtype survival benefit (5-yr OS 77% for basal, 56% for luminal, and 56% for p53-like; p=0.021). Limitations include the small number of pretreatment specimens with sufficient tissue for GEP.

CONCLUSION:

GEP was predictive of clinical UC outcomes. The basal subtype was associated with better survival, and the p53-like subtype was associated with bone metastases and chemoresistant disease.

PATIENT SUMMARY:

We can no longer think of urothelial cancer as a single disease. Gene expression profiling identifies subtypes of urothelial cancer that differ in their natural history and sensitivity to chemotherapy.

KEYWORDS:

Basal; Bevacizumab; Dose-dense methotrexate cisplatin; Gene expression profiling; Luminal; Neoadjuvant; Subtype; Urothelial cancer; p53

PMID:
26343003
PMCID:
PMC4775435
DOI:
10.1016/j.eururo.2015.08.034
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center